Evidence map›Paper›PMID 31232712›Full record

ReviewCurrent opinion in nephrology and hypertension2019

Advances in management of chronic metabolic acidosis in chronic kidney disease.

Wei Chen, Matthew K Abramowitz

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current opinion in nephrology and hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Wei ChenDepartment of Medicine, Albert Einstein College of Medicine, Bronx.
Matthew K AbramowitzDepartment of Medicine, Albert Einstein College of Medicine, Bronx.
Albert Einstein College of Medicine · US

Funding

Calcification Propensity, using Dynamic Light Scattering, to Study Vascular Calcification in Patients with Advanced Chronic Kidney DiseaseK23DK114476 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHEN, WEI · 2018 to 2021
$953k
Inflammation, muscle wasting, and physical function in chronic kidney diseaseK23DK099438 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ABRAMOWITZ, MATTHEW K · 2014 to 2018
$946k
Characterization and novel imaging of skeletal muscle fibrosis in patients with chronic kidney diseaseR03DK116023 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ABRAMOWITZ, MATTHEW K · 2018 to 2019
$182k
NIDDK NIH HHS K23 DK099438NIDDK NIH HHS K23 DK114476NIDDK NIH HHS R03 DK116023
6 · The paper itself

Abstract

purpose of reviewChronic metabolic acidosis is a common complication of chronic kidney disease (CKD) and is associated with adverse consequences, such as CKD progression and muscle wasting. We review the findings from recent clinical trials that have examined the effects of sodium bicarbonate therapy and veverimer in patients with CKD and chronic metabolic acidosis. RECENT

findingsThere are four recent clinical trials on chronic metabolic acidosis of CKD. In a pilot, cross-over study, 6 weeks of sodium bicarbonate therapy improved vascular endothelial function, measured by brachial artery flow-mediated dilation. In a single-center, randomized, open-label study, 6 months of sodium bicarbonate therapy increased muscle mass and lean body mass, and preserved kidney function. The other two clinical trials (phase 1/2 and phase 3 studies) examined the effects of veverimer, which is a hydrochloric acid binder. The phase 3 study showed that 12-weeks of veverimer increased serum bicarbonate levels and might improve physical function. The effects of veverimer on CKD progression, physical function and cardiovascular endpoints as well as its long-term safety are yet to be determined. SUMMARY: Recent studies suggest that sodium bicarbonate therapy may improve vascular endothelial function and muscle mass, and preserve renal function. Veverimer increases serum bicarbonate level and could be a potential new therapeutic option for treating chronic metabolic acidosis.

Indexed as

AcidosisChronic DiseaseClinical Trials as TopicHumansPolymersRenal Insufficiency, ChronicSodium BicarbonatePolymersSodium Bicarbonateveverimer

Identifiers

PMID31232712
PMCPMC6677263
OpenAlexW2950528311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.